Reduction of circulating secretory phospholipase A2 levels by anti- tumor necrosis factor chimeric monoclonal antibody in patients with severe Crohn's disease. Relation between tumor necrosis factor and secretory phospholipase A2 in healthy humans and in active Crohn's disease

Scandinavian Journal of Gastroenterology

Volumn 33, Issue 10, 1998, Pages 1094-1098

  Van Dullemen, H M ^a   Wolbink, G J ^b   Wever, P C ^b   Van Der Poll, T ^b   Hack, C E ^b   Tytgat, G N J ^b   Van Deventer, S J H ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NONE

Author keywords

Crohn's disease; Inflammation; Monoctonal anti tumor necrosis factor antibody; Secretory phospholipase A2 group II; Tumor necrosis factor

Indexed keywords

MONOCLONAL ANTIBODY; PHOSPHOLIPASE A2; RECOMBINANT TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY;

ARTICLE; BIOSYNTHESIS; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE RELEASE; HUMAN; INFLAMMATION; PATHOGENESIS; PRIORITY JOURNAL;

ADULT; ANTIBODIES, MONOCLONAL; CASE-CONTROL STUDIES; CROHN DISEASE; ENZYME INDUCTION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PHOSPHOLIPASES A; RANDOM ALLOCATION; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031762451     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655298750026813     Document Type: Article

References (41)

1. 2. Biochem Biophys Acta 1980;604:101-46.
2. Schoenberg MH, Beger HG. Reperfusion injury after intestinal ischemia [review]. Crit Care Med 1993;21:1376-86.
3. Larsen GL, Henson PM. Mediators of inflammation. Rev Immunol 1983;1:335-59.
4. Irvine RF. How is the level of free arachidonic acid controlled in mammalian cells? Biochem J 1982;204:3-16.
5. 2 expression and pathogenesis of the sepsis syndrome. Circ Shock 1993;39:160-7.
6. 2 levels correlate with the hemodynamic and pulmonary changes in gram negative shock in man. J Lab Clin Med 1984;104:873-81.
7. 2 activity in sera and synovial fluids in rheumatoid arthritis and osteoarthritis. Its possible role as a proinflammatory enzyme. J Rheumatol 1985;12:211-16.
8. 2 correlates with disease activity in rheumatoid arthritis. J Reumatol 1988;14:1351-55.
9. 2 activity in Malawian children with falciparum malaria. Am J Trop Med Hyg 1993;49:455-9.
10. 2 in sera of febrile patients with microbiologically or clinically documented infections. Clin Infect Dis 1993;17:864-70.
11. 2 in acute pancreatitis. Scand J Gastroenterol 1980;15:641-50.
12. 2 immunochemically related to group II enzyme in inflammatory bowel disease: its correlation with disease activity of Crohn's disease and ulcerative colitis. Gut 1992;33: 914-21.
13. 2. Am J Pathol 1989;134:807-11.
14. 2 in rabbit chondrocytes: a possible signal for IL-1 action. J Immunol 1989;136:1283-87.
15. 2. Lab Invest 1986;55:391-404.
16. 2 in human serum. Clin Chem 1992;38:1824-29.
17. 2 in serum of febrile patients with haematological malignancy. Eur J Haematol 1993;50:11-16.
18. 2 gene expression in human hepatoma cells by mediators of the acute phase response. J Biol Chem 1991;266: 2647-51.
19. 2 - a mediator between proximal and distal effectors of inflammation. Immunol Today 1991;12:143-6.
20. 2 enzymes: regulation and inhibition. TiBS 1993;14:92-8.
21. 2 in colonie mucosa of patients with Crohn's disease and ulcerative colitis. Gut 1994: 35:1593-8.
22. 2 protein in sera of patients with Crohn's disease and ulcerative colitis. Am J Gastroenterol 1993;88:1076-80.
23. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91.
24. MacDonald TT, Hutchings P, Choy M, Murch S, Cooke A. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990;81:301-5.
25. Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio PWS, et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of childeren with inflammatory bowel disease. Gastroenterology 1994;106:1455-66.
26. van der Poll T, Buller HR, Ten Cate H, Wortel CH, Bauer KA, van Deventer SJH, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990;322:1622-7.
27. van der Poll T, van Deventer SJH, Hack CE, Wolbink GJ, Aarden LA, Buller HR, et al. Effects on leukocytes after injection of tumor necrosis factor into healthy humans. Blood 1992;79:693-8.
28. van Dullemen HM, van Deventer SJH, Hommes DW, Bijl HA, Jansen J, Tytgat GNJ, et al. Treatment of Crohn's disease with an anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-35.
29. 2 in arthritis plasma using a newly developed sandwich ELISA. Br J Rheum 1992; 31:175-8.
30. Pruzanski W, Stepfanski E, Wilmore DW, Martich GD, Hoffman AGD, Suffredini A. Sequential activation of TNF-phospholipase axis following I.V. endoxin challenge in human volunteers. FASEB J 1990;4:A1714.
31. 2 activity by intravenous infusion of endotoxin in patients with neoplasia. J Immunother 1992;12:242-6.
32. 2 in human volunteers challenged with intravenous endotoxin. Inflammation 1992;16:561-70.
33. 2 following I.V. infusions of tumor necrosis factor in man. Blood 1990;76:A3839.
34. 2 during septic shock. J Lah Clin Med 1991;118:471-5.
35. 1 cells. J Biol Chem 993;268:21875-82.
36. 2 plays a role in arachidonic acid release and eicosanoid biosynthesis by mast cells. J Immunol 1994;152:5438-46.
37. 2 in hospitalized patients. Clin Chim Acta 1989;183:59-64.
38. Hoffmann GE, Guder WG. Serum phospholipase: regulatory and pathophysiological aspects. Klin Wochensehr 1989;67:144-8.
39. Elsbach P, Weiss J. Phagocytosis of bacteria and phospholipid degradation. Biocheni Biophys Acta 1988;947:29-52.
40. 2 in concert with polymorphonuclear leukocytes. J Biol Chem 1994;269:26331-7.
41. 2 on cell-free prothrombinase complex. J Biol Chem 1994;42:26338.